HD LifeSciences Announces Participation in LSI 2021 Emerging Medtech Summit

Boston, MA, May 10, 2021

HD LifeSciences today announced its upcoming participation in the LSI 2021 Emerging Medtech Summit, on May 11-13. Patrick O’Donnell, President & CEO for HD Lifesciences, will be presenting on the company’s Series A growth capital financing plan and the company’s innovative, best in class Hive™ portfolio of 3D printed spinal interbody fusion devices. A rapid growth stage company, HD Lifesciences is driving commercialization activity in the $1.9B U.S. spine interbody market segment through distribution expansion initiatives and new product introductions. The company’s Hive interbody devices are designed with Soft Titanium™ technology, incorporating highly innovative, patented load bearing lattice structure and independent endplates. The distinctive design allows bone cells growing both within the implant’s central cavity as well as perimeter walls to experience natural loads. These innovative features significantly increase bone ingrowth and fusion construct strength while providing improved image capability.

This conference will bring together senior level healthcare investors, strategic buyers and medtech innovators. The 3-day event is focused on the innovators, strategics and investors building the future of healthcare and is an excellent opportunity for innovative startup companies, market leaders, and investors to forge business relationships.


About HD LifeSciences

HD LifeSciences is a pioneer and leading innovator in 3D printed spinal interbody fusion implants and instrumentation. The company’s proprietary, biomimetic Soft Titanium™ technology clearly distinguishes their products in the $1.9B spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provide surgeons and their patients ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration – all features that lead to consistently strong fusion constructs and efficacious clinical experiences.

HD Lifesciences is located in Woburn, Massachusetts U.S.A

Contact: Patrick O’Donnell at patrick.odonnell@hdlifesciences.com

Website: www.hdlifesciences.com

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button